Patients Monitoring During Treatment With Injectable DMDs (INF and GA) (ORP-11)
IFN-β : All interferons are approved for the treatment of RRMS, moreover Betaferon and Avonex are also approved for the treatment of clinical isolated syndrome (CIS) and Betaferon for the treatment of active secondary progressive MS (SPMS) as well (EMA website). Long-term data regarding safety and e...
Main Author: | Zahra Nikoo |
---|---|
Format: | Article |
Language: | English |
Published: |
Iran University of Medical Sciences
2023-01-01
|
Series: | Neurology Letters |
Subjects: | |
Online Access: | https://www.neurologyletters.com/article_184160_d41d8cd98f00b204e9800998ecf8427e.pdf |
Similar Items
-
Patients monitoring during treatment with Dimethyl fumarate (ORP-23)
by: Ali Yousefi Pour
Published: (2023-01-01) -
Patient Monitoring during Treatment with Ocrelizumab and Rituximab (ORP-49)
by: Nazanin Razazian
Published: (2023-01-01) -
Patients monitoring during treatment with Teriflunomide (ORP-41)
by: Nahid Hoseini Nejad Mir
Published: (2023-01-01) -
Physical disability assessment: EDSS calculation (ORP-05)
by: Zahra Ebadi
Published: (2023-11-01) -
Comorbidity in patients with MS (ORP-19)
by: Fereshteh Ashtari
Published: (2023-01-01)